Longitudinal and cross-sectional analyses of visual field progression in participants of the ocular hypertension treatment study

Archives of Ophthalmology

Volumn 128, Issue 12, 2010, Pages 1528-1532

  Artes, Paul H ^a   Chauhan, Balwantray C ^a   Keltner, John L ^b,c   Cello, Kim E ^b   Johnson, Chris A ^d   Anderson, Douglas R ^e   Gordon, Mae O ^f   Kass, Michael A ^f  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; FOLLOW UP; GLAUCOMA; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL FIELD DEFECT;

CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; GLAUCOMA; HUMANS; LONGITUDINAL STUDIES; OCULAR HYPERTENSION; REPRODUCIBILITY OF RESULTS; VISION DISORDERS; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 78650098319     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.292     Document Type: Article

References (20)

1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713, 729-730.
2. Palmberg P. Answers from the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2002;120(6):829-830. (Pubitemid 34620365)
3. Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999;117(5):573-583. (Pubitemid 29218422)
4. Asman P, Heijl A. Glaucoma Hemifield Test: automated visual field evaluation. Arch Ophthalmol. 1992;110(6):812-819.
5. Johnson CA, Keltner JL, Cello KE, et al; Ocular Hypertension Study Group. Baseline visual field characteristics in the Ocular Hypertension Treatment Study. Ophthalmology. 2002;109(3):432-437. (Pubitemid 34187644)
6. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2000;118(9):1187-1194.
7. Heijl A, Lindgren G, Lindgren A, et al. Extended empirical statistical package for evaluation of single and multiple fields in glaucoma: Statpac 2. In: Mills R, Heijl A, eds. Perimetry Update 1990/91. Amsterdam, the Netherlands: Kugler Publications; 1990:303-315.
8. Spry PGD, Johnson CA. Identification of progressive glaucomatous visual field loss. Surv Ophthalmol. 2002;47(2):158-173. (Pubitemid 34256411)
9. Smith SD, Katz J, Quigley HA. Analysis of progressive change in automated visual fields in glaucoma. Invest Ophthalmol Vis Sci. 1996;37(7):1419-1428. (Pubitemid 26177317)
10. Wild JM, Hutchings N, Hussey MK, Flanagan JG, Trope GE. Pointwise univariate linear regression of perimetric sensitivity against follow-up time in glaucoma. Ophthalmology. 1997;104(5):808-815. (Pubitemid 27200879)
11. Gardiner SK, Crabb DP. Examination of different pointwise linear regression methods for determining visual field progression. Invest Ophthalmol Vis Sci. 2002;43(5):1400-1407. (Pubitemid 34462637)
12. McNaught AI, Crabb DP, Fitzke FW, Hitchings RA. Visual field progression: comparison of Humphrey Statpac2 and pointwise linear regression analysis. Graefes Arch Clin Exp Ophthalmol. 1996;234(7):411-418. (Pubitemid 26202575)
13. Artes PH, Nicolela MT, LeBlanc RP, Chauhan BC. Visual field progression in glaucoma: total versus pattern deviation analyses. Invest Ophthalmol Vis Sci. 2005; 46(12):4600-4606. (Pubitemid 44264560)
14. Morgan RK, Feuer WJ, Anderson DR. Statpac 2 glaucoma change probability. Arch Ophthalmol. 1991;109(12):1690-1692.
15. Bengtsson B, Lindgren A, Heijl A, Lindgren G, Asman P, Patella M. Perimetric probability maps to separate change caused by glaucoma from that caused by cataract. Acta Ophthalmol Scand. 1997;75(2):184-188. (Pubitemid 27249867)
16. Heijl A, Leske MC, Bengtsson B, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand. 2003;81(3):286-293. (Pubitemid 36806269)
17. Keltner JL, Johnson CA, Cello KE, et al; Ocular Hypertension Treatment Study Group. Visual field quality control in the Ocular Hypertension Treatment Study (OHTS). J Glaucoma. 2007;16(8):665-669. (Pubitemid 350307626)
18. Cicchetti DV, Feinstein AR. High agreement but low kappa, II: resolving the paradoxes. J Clin Epidemiol. 1990;43(6):551-558. (Pubitemid 20178544)
19. Heijl A, Bengtsson B. Early visual field defects in glaucoma: a study of eyes developing field loss. In: Bucci MG, ed. Glaucoma: Decision Making in Therapy. Milan, Italy: Springer Verlag; 1996:75-78.
20. Katz J. A comparison of the pattern- and total deviation-based Glaucoma Change Probability programs. Invest Ophthalmol Vis Sci. 2000;41(5):1012-1016. (Pubitemid 30187535)